Genelux Corp's Chief Technical Officer, Joseph Cappello, sold 10,257 shares of common stock on August 31, 2026, generating approximately $28,112 in proceeds at a weighted average price of $2.7408 per share.
The transaction was conducted to cover estimated tax obligations arising from the vesting of restricted stock units, according to a filing footnote. Following the sale, Cappello retains direct and beneficial ownership of 318,480 shares of Genelux common stock. The disposal was disclosed in a Form 4 filing dated September 2, 2026.
Genelux's stock, listed under the ticker GNLX on the NASDAQ, was trading at $2.55 on Monday, down $0.05 or 1.92%. The company's shares have declined 11.5% over the past week and 41.5% year-to-date, reflecting broader market pressures.
Separately, Genelux reported continued clinical development of its cancer immunotherapy candidate, Olvi-Vec. Benchmark maintained a "Speculative Buy" rating with a $20 price target, citing Phase 1b/2 data that demonstrated Olvi-Vec's ability to convert the tumor microenvironment from immunosuppressive to immunoreactive by inducing localized inflammation and increasing CD8+ tumor-infiltrating lymphocytes.
At its 2026 Annual Meeting of Stockholders, Genelux elected John Smither as a Class I Director, effective until the 2029 Annual Meeting. The voting breakdown for the director election showed 8,696,891 votes in favor, 3,393,408 votes withheld, and 16,172,901 broker non-votes.
